Literature DB >> 32634235

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse.

Andrew Kent1, Sumithira Vasu2, Derek Schatz1, Natalie Monson1, Steven Devine2, Clayton Smith1, Jonathan A Gutman1, Daniel A Pollyea1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32634235      PMCID： PMC7362348          DOI： 10.1182/bloodadvances.2020001991

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  38 in total

1.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Authors:  Madan Jagasia; Mukta Arora; Mary E D Flowers; Nelson J Chao; Philip L McCarthy; Corey S Cutler; Alvaro Urbano-Ispizua; Steven Z Pavletic; Michael D Haagenson; Mei-Jie Zhang; Joseph H Antin; Brian J Bolwell; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Robert Peter Gale; Vikas Gupta; Stephanie J Lee; Mark Litzow; Daniel J Weisdorf; Mary M Horowitz; Theresa Hahn
Journal:  Blood       Date:  2011-10-18       Impact factor: 22.113

Review 2.  Hedgehog signaling inhibitors in solid and hematological cancers.

Authors:  Jorge E Cortes; Ralf Gutzmer; Mark W Kieran; James A Solomon
Journal:  Cancer Treat Rev       Date:  2019-05-06       Impact factor: 12.111

3.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

4.  Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation.

Authors:  John E Levine; Thomas Braun; Samuel L Penza; Patrick Beatty; Kenneth Cornetta; Rodrigo Martino; William R Drobyski; A John Barrett; David L Porter; Sergio Giralt; Jose Leis; Houston E Holmes; Matthew Johnson; Mary Horowitz; Robert H Collins
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

5.  Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Xiao-Su Zhao; Yan-Rong Liu; Hong-Hu Zhu; Lan-Ping Xu; Dai-Hong Liu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Ann Hematol       Date:  2011-06-28       Impact factor: 3.673

6.  Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.

Authors:  Jorge E Cortes; Hervé Dombret; Akil Merchant; Tetsuzo Tauchi; Christine G DiRienzo; Barbara Sleight; Xiaoxi Zhang; Eric P Leip; Naveed Shaik; Timothy Bell; Geoffrey Chan; Mikkael A Sekeres
Journal:  Future Oncol       Date:  2019-09-13       Impact factor: 3.404

7.  Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.

Authors:  F R Appelbaum; J Anderson
Journal:  Leukemia       Date:  1998-09       Impact factor: 11.528

8.  Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.

Authors:  Jan J Cornelissen; Dimitri Breems; Wim L J van Putten; Alois A Gratwohl; Jakob R Passweg; Thomas Pabst; Johan Maertens; H Berna Beverloo; Marinus van Marwijk Kooy; Pierre W Wijermans; Bart J Biemond; Edo Vellenga; Leo F Verdonck; Gert J Ossenkoppele; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544

9.  Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.

Authors:  Jorge E Cortes; B Douglas Smith; Eunice S Wang; Akil Merchant; Vivian G Oehler; Martha Arellano; Daniel J DeAngelo; Daniel A Pollyea; Mikkael A Sekeres; Tadeusz Robak; Weidong Wendy Ma; Mirjana Zeremski; M Naveed Shaik; A Douglas Laird; Ashleigh O'Connell; Geoffrey Chan; Mark A Schroeder
Journal:  Am J Hematol       Date:  2018-09-09       Impact factor: 10.047

10.  CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.

Authors:  Marcos de Lima; Betul Oran; Richard E Champlin; Esperanza B Papadopoulos; Sergio A Giralt; Bart L Scott; Basem M William; Joel Hetzer; Eric Laille; Becky Hubbell; Barry S Skikne; Charles Craddock
Journal:  Biol Blood Marrow Transplant       Date:  2018-06-20       Impact factor: 5.742
View more
  3 in total

Review 1.  Relapsed acute myeloid leukemia in children and adolescents: current treatment options and future strategies.

Authors:  Sara Zarnegar-Lumley; Kenneth J Caldwell; Jeffrey E Rubnitz
Journal:  Leukemia       Date:  2022-06-06       Impact factor: 12.883

Review 2.  Maintenance therapy for AML after allogeneic HCT.

Authors:  Rahul K Nayak; Yi-Bin Chen
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

Review 3.  PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Christina-Nefeli Kontandreopoulou; Panagiotis T Diamantopoulos; Despina Tiblalexi; Nefeli Giannakopoulou; Nora-Athina Viniou
Journal:  Blood Adv       Date:  2021-11-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.